Approval was increasingly expected, so the surprise is limited. The FDA had already accepted the resubmitted application with an August 2, 2026 action goal, and the late-July advisory panel supported approval, making an approval outcome largely anticipated rather than a fresh shock.
The filing delivers the key de-risking event: a usable commercial label. TUDRIQEV is approved with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking regimen, with no requirement for prior BRAF treatment and flexibility to inject superficial, deep, lung, liver, and other visceral lesions (U.S. Prescribing Information). The label also permits physician-discretion retreatment and does not require TUDRIQEV and nivolumab to be administered on the same day (Label Highlights).
| Metric | Filing figure | What it means |
|---|---|---|
| Efficacy-evaluable population | 91 patients | Patients had at least one non-injected lesion (IGNYTE Study: Basis of Accelerated Approval) |
| Objective response rate | 24.2% | Responses assessed by blinded central review (Prescribing Information: Efficacy Summary) |
| Median duration of response | 14.1 months | Lower confidence bound was 10.7 months; upper bound not reached (Prescribing Information: Efficacy Summary) |
| Responses lasting over 12 months | 54.6% | Observed duration of response (Prescribing Information: Efficacy Summary) |
| Estimated addressable U.S. patients | ~10,000 | Company estimate across treatment lines for injectable patients after PD-1 progression (U.S. Melanoma Patient Treatment Funnel) |
| Expected commercial shipment timing | Approximately 60 days | Initial product availability is not immediate (Pillars to Drive Long-Term Value) |
The commercial setup is stronger than a bare approval announcement. Replimune describes a targeted launch across roughly 200 early-adopter accounts, expanding toward approximately 450 accounts initially and 1,200 accounts over the longer term; it also says existing procedural codes support injections and payer engagement covers nearly 80% of covered lives (Targeted Launch; Reimbursement Model). Those details reduce—but do not eliminate—the practical access and administration risk for an injectable therapy.
The approval still carries a material scientific and regulatory condition. It is accelerated approval based on response rate and response duration, with continued approval contingent on verification of clinical benefit in the randomized IGNYTE-3 study, which is designed to compare TUDRIQEV plus nivolumab with physician's choice and has overall survival as its primary endpoint (FDA Approval; Confirmatory IGNYTE-3 Study). That means the filing unlocks revenue potential but does not yet validate the therapy against a control arm.
Net: modestly better than the immediate pre-decision setup, not a full reset of the story. Approval removes the largest near-term regulatory obstacle and starts the path to first revenue, but the outcome was substantially anticipated after the advisory-panel result, while launch execution, product availability in roughly 60 days, and IGNYTE-3 remain the major unresolved value drivers.
Read the original 8-K on SEC EDGAR ↗